Classification | ||||
Criteria | CR | PR | SD | PD |
WHO | 100% reduction in tumor size | ≥50% reduction in tumor size | ≥25% and ≤50% reduction in tumor size | ≥25% increase in tumor size |
EORTC | Reduction of 18F-FDG uptake to background levels | ≥15% reduction in 18F-FDG uptake | ≤15% reduction and ≤25% increase in 18F-FDG uptake | ≥25% increase in 18F-FDG uptake |
RECIST | 100% reduction in tumor size | ≥30% reduction in tumor size | ≤30% reduction and ≤20% increase in tumor size | ≥20% increase in tumor size |
PERCIST | Reduction of 18F-FDG uptake to level of background blood pool | ≥30% reduction in peak SUL | ≤30% reduction or increase in peak SUL | ≥20% increase in peak SUL |
IWC | Reduction of nodes to normal size | ≥50% reduction in size of 6 largest nodes | ≤50% reduction or increase in size of nodes | ≥50% increase in size of nodes |
IWC+PET | CR by IWC plus negative PET scan | CR/PR by IWC plus positive PET scan | SD by IWC plus positive PET scan | PD by IWC plus positive PET scan |
International Harmonization Project | PET− nodes or PET+ nodes of normal size | ≥50% reduction in size of 6 largest nodes | New PET+ nodes | New PET+ ≥1.5 cm or ≥50% increase in size of existing nodes |
D5PS* | 18F-FDG uptake at background level | 18F-FDG uptake ≤ mediastinal blood pool/liver activity | Mediastinal blood-pool activity ≤ 18F-FDG uptake ≤ liver activity | 18F-FDG uptake > liver activity |
Lugano | ||||
PET/CT | Normalized 18F-FDG uptake (1–3 on D5PS) | Reduced 18F-FDG uptake (4–5 on D5PS) | Unchanged 18F-FDG uptake (4–5 on D5PS) | Increased 18F-FDG uptake (4–5 on D5PS) + new lesions |
CT | Reduction of nodes/organs to normal size | ≥50% reduction in size of up to 6 nodes/spleen | <50% reduction in size of up to 6 nodes | ≥50% increase in size of node + new lesions |
↵* D5PS was converted from 5-point scale to 4 categories of CR, PR, SD, and PD (1 = CR, 2 = PR, 3 = SD, 4/5 = PD).
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.